Last reviewed · How we verify
Tetravac TM
Tetravac is a tetravalent vaccine that provides immunological protection against four distinct pathogens or disease targets through simultaneous antigenic stimulation.
Tetravac is a tetravalent vaccine that provides immunological protection against four distinct pathogens or disease targets through simultaneous antigenic stimulation. Used for Prevention of four vaccine-preventable diseases (specific pathogens not publicly detailed in available sources).
At a glance
| Generic name | Tetravac TM |
|---|---|
| Also known as | DTPa-IPV |
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine formulation combines four separate antigenic components to elicit immune responses against multiple targets in a single administration. This polyvalent approach allows for broader protection and reduced number of injections compared to monovalent vaccines. The specific mechanism depends on the target pathogens, which may include viral or bacterial antigens designed to stimulate both humoral and cellular immunity.
Approved indications
- Prevention of four vaccine-preventable diseases (specific pathogens not publicly detailed in available sources)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |